In Re Brimonidine Patent Litigation [Erratum], 2010-1102 (2011)
Court: Court of Appeals for the Federal Circuit
Number: 2010-1102
Visitors: 12
Filed: Aug. 16, 2011
Latest Update: Feb. 22, 2020
Summary: United States Court of Appeals for the Federal Circuit _ August 16, 2011 ERRATUM _ Appeal No. 2010-1102,-1103 IN RE BRIMONIDINE PATENT LITIGATION - ALLERGAN, INC., v. EXELA PHARMSCI INC. and EXELA PHARMSCI PVT., LTD., and APOTEX INC. and APOTEX CORP., Decided: May 19, 2011 Precedential Opinion _ Please make the following change: Page 11, footnote 1, lines 9-10, the text should be changed to read Dose Response Study” (“Derick”). The dissent characterizes that article
United States Court of Appeals for the Federal Circuit ______________________ August 16, 2011 ERRATUM ______________________ Appeal No. 2010-1102,-1103 IN RE BRIMONIDINE PATENT LITIGATION ---------------------------------------------- ALLERGAN, INC., v. EXELA PHARMSCI INC. and EXELA PHARMSCI PVT., LTD., and APOTEX INC. and APOTEX CORP., Decided: May 19, 2011 Precedential Opinion ______________________ Please make the following change: Page 11, footnote 1, lines 9-10, the text should be changed to read Dose Response Study” (“Derick”). The dissent characterizes that article
Source: CourtListener
